Drugs / NEXI-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06572631 | Jun 2025 → Dec 2026 | acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04284228 | Feb 2020 → Oct 2024 | acute myeloid leukemia, myelodysplastic syndrome | NexImmune Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-05 | NexImmune Inc. | Results NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting neximmune.com ↗
In this clinical trial to date, NEXI-001 is well tolerated with a favorable safety profile while eliciting an immune response to target antigens and a clinical effect in some patients. |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEXI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04284228 ↗ |
| Modality | Cell therapy | “The NEXI-001 is an adoptive cellular therapy product” NCT04284228 ↗ |
| Route | Intravenous | “a single IV infusion of the NEXI-001 T cell product” NCT04284228 ↗ |